Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low‐density lipoprotein receptor knockout mice
Sign Up to like & getrecommendations! Published in 2018 at "Cardiovascular Therapeutics"
DOI: 10.1111/1755-5922.12476
Abstract: AIMS Despite the therapeutic efficacy of statins and antiplatelet agents for atherosclerosis, monotherapy with each drug alone is often insufficient to achieve the patient's therapeutic goals. We previously showed that combined statin/antiplatelet agent/anti-tumor necrosis factor… read more here.
Keywords: pravastatin cilostazol; therapy; density lipoprotein; pravastatin ... See more keywords